Alphabet’s Isomorphic Labs in talks to raise at $40B+ valuation

The headline number is less telling than what it implies: Alphabet is willing to let an outside valuation anchor a unit still inside its own structure, a signal that AI drug discovery is being priced as a standalone asset class rather than a research line item. That matters for the broader RWA and biotech-adjacent tokenization narrative, where privately held pipeline value is the raw material everyone wants to make liquid. What's worth watching is whether any capital actually converts at that mark, and whether the eventual holders are strategics or financial players — the composition, not the size, will say how real this market is.